Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

94.28 +0.16 (+0.16%)

Streaming Delayed Price Updated: 3:50 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

26 27 Next >

Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗

December 06, 2023

Despite its impressive fundamentals, INCYTE CORP (NASDAQ:INCY) remains undervalued.

Via Chartmill

Investors should take note of NASDAQ:INCY, a growth stock that remains attractively priced. ↗

November 28, 2023

Investors should take note ofINCYTE CORP (NASDAQ:INCY), a growth stock that remains attractively priced.

Via Chartmill

Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness ↗

November 21, 2023

Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US

Via Benzinga

The Latest Analyst Ratings for Incyte ↗

November 21, 2023

Via Benzinga

Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents. ↗

November 14, 2023

Investors should take notice ofINCYTE CORP (NASDAQ:INCY)—it offers a great deal for the fundamentals it presents.

Via Chartmill

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 ↗

November 12, 2023

Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.

Via InvestorPlace

Looking for growth without the hefty price tag? Consider NASDAQ:INCY. ↗

November 06, 2023

Looking for growth without the hefty price tag? Consider INCYTE CORP (NASDAQ:INCY).

Via Chartmill

Earnings Outlook For Incyte ↗

October 30, 2023

Via Benzinga

Expert Ratings for Incyte ↗

September 21, 2023

Via Benzinga

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know ↗

November 02, 2023

Via Benzinga

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

November 02, 2023

From Incyte

Via Business Wire

Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

October 31, 2023

From Incyte

Via Business Wire

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

October 27, 2023

From Incyte

Via Business Wire

NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases. ↗

October 23, 2023

INCYTE CORP (NASDAQ:INCY) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Incyte to Present at Upcoming Investor Conferences

October 18, 2023

From Incyte

Via Business Wire

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

October 16, 2023

From Incyte

Via Business Wire

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

October 13, 2023

From Incyte

Via Business Wire

Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

October 13, 2023

From Incyte

Via Business Wire

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

October 11, 2023

From Incyte

Via Business Wire

Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity

October 11, 2023

From Incyte

Via Business Wire

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

October 11, 2023

From Incyte

Via Business Wire

Incyte to Report Third Quarter Financial Results

October 10, 2023

From Incyte

Via Business Wire

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

September 29, 2023

From Incyte

Via Business Wire

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

Pancreatic Cancer Battle Boosted by $200M VC Firm

September 19, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison ↗

September 18, 2023

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...

Via Benzinga

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival ↗

September 18, 2023

Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.

Via Investor's Business Daily

Incyte to Present at Upcoming Investor Conferences

August 22, 2023

From Incyte

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Delivering useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/pages/Cabling-Installation-and-Maintenance/298118662118

https://www.instagram.com/cim_magazine/

https://www.linkedin.com/company/3962332

http://twitter.com/CABLINGMAG

Affiliated Brands

DATA CENTER FRONTIER

ISE

LIGHTWAVE

DIGITAL INFRASTRUCTURE GROUP

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions